Vas Narasimhan

Vasant "Vas" Narasimhan is the CEO of Novartis, one of the world's largest pharmaceutical companies, headquartered in Basel, Switzerland. Born in 1976 in the United States to Indian immigrant parents, Narasimhan earned an MD from Harvard Medical School and a public policy degree from Harvard's Kennedy School. He joined Novartis in 2005 and rose rapidly through development and commercial roles before being appointed CEO in 2018 at age 41 — the youngest leader of a major pharma company in decades. Narasimhan's defining strategic move has been the transformation of Novartis from a diversified healthcare conglomerate into a focused innovative medicines company. He completed the spin-off of the Sandoz generics business in 2023, divested the Alcon eye care division, and concentrated the company's resources on five core therapeutic platforms: cardiovascular, immunology, neuroscience, solid tumors, and hematology. This focus has sharpened Novartis's R&D pipeline and simplified the investment thesis. His scientific background differentiates him from many pharma CEOs who come from commercial or finance tracks. Narasimhan has pushed Novartis to the forefront of next-generation therapy platforms including radioligand therapy (Pluvicto for prostate cancer), cell and gene therapy, and RNA therapeutics. He has also invested heavily in data science and AI-enabled drug discovery, partnering with Microsoft and building internal capabilities to accelerate clinical development timelines. Under Narasimhan's leadership, Novartis has delivered consistent above-market growth in innovative medicines while improving operating margins through his productivity and efficiency program. He has navigated the company through patent cliffs, generic competition, and the complex post-pandemic pharma landscape. His combination of medical training, policy expertise, and corporate strategy makes him one of the most technically credentialed CEOs in the global pharmaceutical industry.